B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia
FATEFate TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for FT819 (CAR-19, TCR-KO) in B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia. The expected timing is based on the latest available company guidance and may change.
02/26/24- Dose escalation ongoing. 5/9/24 Translational Data at ASGCT '24. 8/12/25- To initiate individual DE cohorts in H2 2025 for AAV, IIM, & SSc. 11/13/25:- FT819 autoimmune Ph1 data and ex-US expansion discussed; no new oncology trial updates provided. 02/26/26:- FT819-102 autoimmune basket expanding outpatient treatment; SSc and IIM patients treated; clinical/regulatory updates planned H2 2026. 05/13/26:- FT819-102 Phase 1 autoimmune basket now at 18 sites; 27 patients treated; further updates planned H2 2026. 08/13/26:- FT819 updates concerned autoimmune indications; no new update for listed oncology indications.
Verification
Confirm timing and program details against the company announcement or filing.